Literature DB >> 9012694

Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma.

T Tasaka1, J Berenson, R Vescio, T Hirama, C W Miller, M Nagai, J Takahara, H P Koeffler.   

Abstract

To study the structural integrity of the cyclin-dependent kinase inhibitors known as INK4A (p16), INK4B (p15) and INK4C (p18) in multiple myeloma, we examined 20 primary myeloma samples (including one case of plasma cell leukaemia) using polymerase chain reaction-single strand conformation polymorphism, and 17 samples were examined by Southern blot analysis. The plasma cell leukaemia sample had homozygous deletions of the p15 and p16 genes (6%). One myeloma case had a p15 gene homozygous deletion (6%) with an intact p16 gene. This sample also had a p18 homozygous deletion, suggesting that the deletion of both genes may be important in either the development or progression of myeloma. No point mutations of these INK4 genes were found in the 20 samples. This is the first report that indicates that deletions of p15, p16 and p18 genes occur in some individuals with multiple myeloma (2/17 cases).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012694     DOI: 10.1046/j.1365-2141.1997.8552482.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Frequent loss of 1p32 region but no mutation of the p18 tumor suppressor gene in meningiomas.

Authors:  P Leuraud; Y Marie; E Robin; S Huguet; J He; K Mokhtari; P Cornu; K Hoang-Xuan; M Sanson
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.

Authors:  J Boström; B Meyer-Puttlitz; M Wolter; B Blaschke; R G Weber; P Lichter; K Ichimura; V P Collins; G Reifenberger
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

4.  Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility.

Authors:  S L Zhang; W DuBois; E S Ramsay; V Bliskovski; H C Morse; L Taddesse-Heath; W C Vass; R A DePinho; B A Mock
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

5.  CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.

Authors:  Fenghuang Zhan; Simona Colla; Xiaosong Wu; Bangzheng Chen; James P Stewart; W Michael Kuehl; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2007-02-15       Impact factor: 22.113

Review 6.  Molecular aspects of multiple myeloma.

Authors:  G Pratt
Journal:  Mol Pathol       Date:  2002-10

Review 7.  Conspirators in a capital crime: co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in glioblastoma multiforme.

Authors:  David A Solomon; Jung-Sik Kim; Walter Jean; Todd Waldman
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

8.  Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors.

Authors:  Sefat E Khuda; William M Loo; Siegfried Janz; Brian Van Ness; Loren D Erickson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

9.  Germinal center B-cells resist transformation by Kras independently of tumor suppressor Arf.

Authors:  Chelsea D Mullins; Mack Y Su; Vishwanathan Hucthagowder; Liang Chu; Lan Lu; Shashikant Kulkarni; Deborah Novack; Ravi Vij; Michael H Tomasson
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

10.  Deletions of CDKN2C in multiple myeloma: biological and clinical implications.

Authors:  Paola E Leone; Brian A Walker; Matthew W Jenner; Laura Chiecchio; Gianpaolo Dagrada; Rebecca K M Protheroe; David C Johnson; Nicholas J Dickens; Jose Luis Brito; Monica Else; David Gonzalez; Fiona M Ross; Selina Chen-Kiang; Faith E Davies; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.